HC Wainwright set a $12.00 target price on Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note issued to investors on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.

PIRS has been the topic of a number of other research reports. BidaskClub upgraded shares of Pieris Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Monday, February 5th. ValuEngine lowered shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, William Blair started coverage on shares of Pieris Pharmaceuticals in a research report on Wednesday, January 17th. They set an outperform rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Pieris Pharmaceuticals has a consensus rating of Buy and a consensus target price of $10.00.

Pieris Pharmaceuticals (PIRS) opened at $8.59 on Friday. Pieris Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $8.79.

In related news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 4.05% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Baird Financial Group Inc. acquired a new stake in Pieris Pharmaceuticals in the fourth quarter valued at approximately $477,000. Arrowstreet Capital Limited Partnership acquired a new stake in Pieris Pharmaceuticals in the fourth quarter valued at approximately $3,370,000. Virtus Fund Advisers LLC acquired a new stake in Pieris Pharmaceuticals in the fourth quarter valued at approximately $432,000. BlackRock Inc. boosted its position in Pieris Pharmaceuticals by 4.4% in the fourth quarter. BlackRock Inc. now owns 1,596,382 shares of the biotechnology company’s stock valued at $12,053,000 after buying an additional 67,895 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Pieris Pharmaceuticals by 354.8% in the fourth quarter. Wells Fargo & Company MN now owns 82,603 shares of the biotechnology company’s stock valued at $623,000 after buying an additional 64,439 shares in the last quarter. Hedge funds and other institutional investors own 50.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/02/12/pieris-pharmaceuticals-pirs-given-a-12-00-price-target-at-hc-wainwright.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.